Osimertinib-resistant NSCLC cells enhance OXPHOS activity [38], and BRAF inhibitor-resistant melanomas activate PGC-1α-mediated mitochondrial biogenesis, further increasing the cristae density and elevating oxidative capacity [39]. This evidence concerns the gene BRAF and melanoma.